Glaxo set for output boost - Business - Evening Standard
       

Glaxo set for output boost

Britain's GlaxoSmithKline has already benefited from fears that there could be a flu pandemic. In the first three months of this year governments around the world ordered about £220 million worth of Glaxo's flu drug Relenza, outstripping for the first time orders placed for Swiss rival Roche's Tamiflu, according to data supplied by both companies.

About £182 million of Tamiflu was ordered and the switch in demand came after experts warned that the flu strain H1N1, which includes swine flu, was becoming resistant to Tamiflu. James Knight, analyst at Colins Stewart, said Relenza still has "upside", predicting peak sales of £250 million a year.

Comments

Don't Miss
Rock star: Erin Wasson

Rock star

Erin Wasson is the ultimate anti-supermodel
Maybe it’s because she’s a Londoner … Happy anniversary, Ma’am

Happy anniversary

The monarchy has become stronger and more respected in the past 60 years
Victoria Coren: My obsession with children, five proposals a week and why David and I are no power couple

Victoria Coren

David Mitchell and I are no power couple
The Royal Academy of Arts Summer Exhibition preview party

Summer party

Stars at the The Royal Academy of Arts
London gets ready for the Diamond Jubilee - in pictures

Diamond Jubilee

London gets ready - in pictures
The Glamour Awards - stars turn on the style

Glamour Awards

Stars turn on the style
Duchess of Cambridge is pretty in pink at her first Buckingham Palace garden party

Garden party

Duchess of Cambridge is pretty in pink
FIRST review of Ridley Scott's latest sci-fi blockbuster Prometheus

First review

Is Ridley Scott's Prometheus any good?
Fair-weather goths

Fair-weather goths

The sultry shades of summer darks are coming out of the shadows
Dog save the Queen: Corgis surge in popularity

Dog save the Queen

Corgis surge in popularity